F M Investments LLC Cuts Stock Holdings in Integer Holdings Co. (NYSE:ITGR)

F M Investments LLC decreased its position in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) by 54.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,283 shares of the medical equipment provider's stock after selling 52,881 shares during the quarter. F M Investments LLC owned approximately 0.13% of Integer worth $5,868,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ITGR. Mather Group LLC. lifted its position in shares of Integer by 304.3% in the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Lee Danner & Bass Inc. bought a new stake in Integer during the 4th quarter valued at approximately $27,000. R Squared Ltd purchased a new position in Integer in the 4th quarter worth approximately $44,000. Versant Capital Management Inc boosted its stake in Integer by 98.4% in the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 183 shares during the period. Finally, Principal Securities Inc. grew its holdings in Integer by 31.2% during the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider's stock valued at $85,000 after buying an additional 152 shares in the last quarter. Institutional investors own 99.29% of the company's stock.

Wall Street Analyst Weigh In

ITGR has been the subject of a number of research reports. Benchmark upped their target price on shares of Integer from $140.00 to $150.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Truist Financial dropped their price objective on shares of Integer from $163.00 to $140.00 and set a "buy" rating for the company in a report on Friday. Raymond James assumed coverage on Integer in a report on Friday, March 28th. They issued an "outperform" rating and a $145.00 target price on the stock. KeyCorp raised their target price on shares of Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Finally, Oppenheimer cut Integer from an "outperform" rating to a "market perform" rating in a research note on Friday, February 21st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Integer currently has a consensus rating of "Moderate Buy" and a consensus price target of $146.00.

Integer Trading Down 1.5 %

Shares of ITGR traded down $1.78 during trading hours on Tuesday, reaching $116.19. 402,352 shares of the company traded hands, compared to its average volume of 344,944. The firm has a market cap of $4.05 billion, a price-to-earnings ratio of 34.58, a PEG ratio of 1.72 and a beta of 1.09. Integer Holdings Co. has a 12-month low of $104.93 and a 12-month high of $146.36. The stock's fifty day moving average price is $123.40 and its 200 day moving average price is $130.90. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62.

Integer (NYSE:ITGR - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts' consensus estimates of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The company had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Sell-side analysts forecast that Integer Holdings Co. will post 6.01 earnings per share for the current year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.